Trastuzumab and Vinorelbine in Advanced Breast Cancer
Status:
Terminated
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see what effects trastuzumab in combination with
vinorelbine has on breast cancer when the participant has circulating tumor cells that are
positive for the protein called HER2. Trastuzumab is an FDA approved drug that targets HER2.
The drug combination of trastuzumab and vinorelbine is an effective treatment for patients
with breast cancers that are positive for HER2. This trial seeks to determine if the
combination can also benefit participants whose original breast cancer was HER2 negative but
whose circulating tumor cells are HER2 positive.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc. Massachusetts General Hospital